Baselga J et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A Phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract S3-3.
Bear HD et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Proc ASCO 2011;Abstract LBA1005.
Burris HA 3rd et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29(4):398-405. Abstract
Cancello G et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat 2011;127:713-20. Abstract
Coleman RE et al. Adjuvant treatment with zoledronic acid in Stage II/III breast cancer. The AZURE trial (BIG 01/04). San Antonio Breast Cancer Symposium 2010;Abstract S4-5.
Cortes J et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet 2011;377(9769):914-23. Abstract
Ellis PA et al. Ongoing clinical development of lapatinib in HER2-positive (HER2+) metastatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies. Proc ASCO 2011;Abstract TPS105.
Gerber B et al. Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 686 triple-negative primary breast cancers: Secondary endpoint analysis of the GeparQuinto study (GBG 44). Proc ASCO 2011;Abstract 1006.
Gianni L et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized Phase II study ('NeoSphere'). San Antonio Breast Cancer Symposium 2010;Abstract S3-2.
Giuliano AE et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA 2011;305:569-75. Abstract
Giuliano AE et al. ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node. Proc ASCO 2010;Abstract CRA506.
Gnant M et al. Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12. Proc ASCO 2011;Abstract 520.
Gonzalez-Angulo AM et al. SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. Proc ASCO 2011;Abstract TPS104.
Loibl S et al. 313 Patients with breast cancer during pregnancy — Results from a prospective and retrospective registry (GBG-20/BIG02-03). San Antonio Breast Cancer Symposium 2010;Abstract S6-2.
O’Shaughnessy J et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). Proc ASCO 2011;Abstract 1007.
Patterns of Care: Breast Cancer Edition, Issue 1, 2011. Available at: http://www.researchtopractice.com/POCB111.
Twelves C et al. The relationship between age and survival outcomes for eribulin in metastatic breast cancer. Proc ASCO 2011;Abstract 1060.
Untch M et al. Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: Primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44). San Antonio Breast Cancer Symposium 2010;Abstract S3-1.
Verma S et al. EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen. Proc ASCO 2011;Abstract TPS116.
Von Minckwitz G et al. Neoadjuvant chemotherapy with or without bevacizumab: Primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44). San Antonio Breast Cancer Symposium 2011;Abstract S4-6.
Von Minckwitz G et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27(12):1999-2006. Abstract
ALTTO: A randomised, multi-centre, open-label, Phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer. NCT00490139.
A Phase II trial of adjuvant paclitaxel and trastuzumab for node-negative HER2-positive breast cancer. NCT00542451.
BETH: A multicenter Phase III randomized trial of adjuvant therapy for patients with HER2-positive node-positive or high risk node-negative breast cancer comparing chemotherapy plus trastuzumab with chemotherapy plus trastuzumab plus bevacizumab. NCT00625898.
NSABP-B-34: A clinical trial comparing adjuvant clodronate therapy vs placebo in early-stage breast cancer patients receiving systemic chemotherapy and/or hormonal therapy or no therapy. NCT00009945.
SWOG-S0307: Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer. NCT00127205.